JUVISYNC Drug Patent Profile
✉ Email this page to a colleague
When do Juvisync patents expire, and when can generic versions of Juvisync launch?
Juvisync is a drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this drug.
This drug has fifty-two patent family members in forty countries.
The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this compound. Additional details are available on the simvastatin; sitagliptin phosphate profile page.
DrugPatentWatch® Generic Entry Outlook for Juvisync
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 11, 2026. This may change due to patent challenges or generic licensing.
There have been twenty-six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for JUVISYNC
International Patents: | 52 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for JUVISYNC |
DailyMed Link: | JUVISYNC at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for JUVISYNC
Generic Entry Date for JUVISYNC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for JUVISYNC
US Patents and Regulatory Information for JUVISYNC
JUVISYNC is protected by one US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of JUVISYNC is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting JUVISYNC
Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Expired US Patents for JUVISYNC
International Patents for JUVISYNC
See the table below for patents covering JUVISYNC around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Lithuania | C1412357 | ⤷ Try a Trial | |
Costa Rica | 8117 | SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV | ⤷ Try a Trial |
China | 1582149 | ⤷ Try a Trial | |
Hong Kong | 1019204 | ⤷ Try a Trial | |
China | 1832949 | Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor | ⤷ Try a Trial |
European Patent Office | 1520582 | ⤷ Try a Trial | |
Portugal | 1412357 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for JUVISYNC
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1412357 | C01412357/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: SCHERING CORPORATION, US |
0896538 | 08C0008 | France | ⤷ Try a Trial | PRODUCT NAME: VILDAGLIPTINE OU UN DE SES SELS PHARMACETIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/414/001 DU 20070926; REGISTRATION NO/DATE AT EEC: EU/1/07/414/001-017 DU 20070926 |
1084705 | CA 2014 00066 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ALOGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER ALOGLIPTIN BENZOATE; REG. NO/DATE: EU/1/13/844/001-027 20130919 |
1084705 | SPC/GB14/082 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTIN; REGISTERED: UK EU/1/07/383/001-018 20070323; UK EU/1/07/382/001-018 20070323 |
1084705 | SPC/GB14/085 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: SAXAGLIPTIN; REGISTERED: UK EU/1/09/545/001-010 20091005 |
1412357 | PA2007006,C1412357 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/383/001-EU/1/07/383/018 20070321 |
1412357 | C20080004 00019 | Estonia | ⤷ Try a Trial | PRODUCT NAME: JANUMET - SITAGLIPTIIN / METFORMIINVESINIKKLORIID |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |